This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Patients were randomised 2:2:1 to receive indacaterol 400 µg or 800 µg or placebo once-daily (between 07:00 and 11:00 h) via a single-dose dry-powder inhaler for 28 days. Assessments included monitoring of adverse events (AEs), blood chemistry (including serum potassium and blood glucose), vital signs (blood pressure and heart rate), electrocardiograms and spirometry.
One hundred and sixty-three patients were randomised, with 155 (95%) completing the study. There were no statistically significant differences between treatment groups in the overall incidence of AEs, with AEs reported by 35%, 51% and 25% of patients in the indacaterol 400 µg, 800 µg and placebo groups, respectively. The majority of AEs were mild or moderate in severity, and there were no study-drug related serious AEs. There were no statistically significant differences between indacaterol groups and placebo in mean pulse rate and QTc interval, and isolated statistically significant (p<0.05) treatment-placebo differences in mean blood pressure, blood glucose and serum potassium.
There was a statistically significant improvement in FEV 1 vs placebo at all postbaseline timepoints for both indacaterol treatment groups; 30 minutes post-dose, adjusted mean±SE FEV 1 indacaterol-placebo differences were: Day 1, 220±36 ml and 210±36 ml; Day 14, 320±50 ml and 270±50 ml; Day 28, 260±61 ml and 200±61 ml for 400 and 800 µg, respectively (all p<0.01 vs placebo). Bronchodilation was still apparent after 24 hours, with pre-dose (i.e. trough) adjusted mean±SE FEV 1 indacaterol-placebo differences of: Day 14, 230±44 ml and 210±44 ml; Day 28, 220±49 ml and 210±49 ml for indacaterol 400 µg and 800 µg, respectively (all p<0.0001 vs placebo).
Once-daily indacaterol was well tolerated at doses up to 800 µg with a good overall safety profile. There was no statistical difference at any dose between the safety of indacaterol and placebo. Furthermore, this study supports the previously demonstrated 24-hour bronchodilator efficacy of indacaterol.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterised by progressive airway obstruction, resulting in airflow limitation that is only partially reversible [1] . COPD represents a major cause of morbidity and mortality worldwide and is therefore associated with high levels of social and economic burden [1] . The Global Initiative for Chronic
Obstructive Lung Disease (GOLD), which provides physicians with guidance on appropriate management of COPD, recommends the implementation of a stepwise treatment plan to manage COPD [1] . Central to control of dyspnoea in COPD are bronchodilators, such as β 2 -agonists: GOLD guidelines recommend regular treatment with one or more long-acting bronchodilators in patients with moderate-to-severe COPD [1] . Two long-acting β 2 -agonists are currently available, formoterol and salmeterol, both of which have approximately 12-hour durations of action at recommended doses and therefore must be taken twice daily [2] [3] [4] [5] [6] [7] .
The only once-daily bronchodilator available at present is the anticholinergic tiotropium, which has a duration of action of at least 24 hours [8, 9] .
Indacaterol is a novel once-daily β 2 -agonist being developed for the treatment of COPD and asthma. Preclinical study results suggest that indacaterol has a longer duration of action than either formoterol or salmeterol, with a rapid onset of action, and a potentially greater cardiovascular safety margin compared with formoterol or salmeterol, for a given degree of bronchodilator activity [10] . In clinical studies in patients with asthma, indacaterol has demonstrated effective 24-hour bronchodilation with a rapid onset of action and was shown to be well tolerated with a good overall safety profile [11, 12] .
The primary objective of the current study was to compare the safety and tolerability of once-daily administration of two doses of indacaterol (400 µg and 800 µg) with that of placebo, over a 28-day period, in patients with moderate COPD. Particular attention was paid to the key safety parameters for this class of drug, namely serum potassium, blood glucose, heart rate, blood pressure, QTc interval and adverse events (AEs) such as tremor, headache and nervousness. A secondary objective was to explore the bronchodilator efficacy of indacaterol, in terms of the effects on lung function. 
Design
This was a phase II, multinational, double-blind, randomised, placebo-controlled, parallel-group study in patients with COPD. Enrolled patients entered a 2-week run-in period and were subsequently randomised to receive 28 days of study treatment, with a 7-day follow-up period to monitor AEs after study-drug cessation. The study was conducted according to Good Clinical Practice Guidelines and in accordance with the Declaration of Helsinki (1964 and subsequent revisions). The study received Institutional Review Board approval, and all patients gave written informed consent prior to the start of the study.
Inclusion and exclusion criteria
Male and female patients aged 40-75 years with a diagnosis of moderate COPD as defined by the 2001 GOLD Guidelines [13] were eligible for enrolment, provided they had a smoking history of at least 10 pack-years and their forced expiratory volume in one second (FEV 1 ) was <70% of their forced vital capacity (FVC). In addition, patients were required to have an FEV 1 30-70% of the Quanjer predicted normal value [14] , when measured after a washout period of at least 6 hours during which no short-acting β 2 -agonist was inhaled, and at least 24 hours after the last use of a long-acting β 2 -agonist.
Patients were excluded if they had a recent respiratory tract infection or COPD exacerbation, if they had a history of asthma (blood eosinophil count >500/mm 3 or an onset of symptoms prior to the age of 40 years), or if they had a significant unstable cardiovascular or metabolic comorbidity. Patients were also excluded if they had used any of the following:
tiotropium bromide within 7 days of run-in or ipratropium bromide, inhalers combining inhaled corticosteroids and β 2 -agonists, or long-acting β 2 -agonists within 24 hours of run-in.
A c c e p t e d m a n u s c r i p t Dose selection was based on a previous study in patients with bronchial asthma where an effective dose was considered to be in the range of 200-400 µg [11] . The present study was therefore designed to examine the safety, tolerability and efficacy of doses considered up to approximately twice the anticipated therapeutic dose for asthma.
Inhaled salbutamol was provided as rescue medication to be used as needed throughout the run-in and treatment periods. Rescue salbutamol was not to be taken within 6
hours of the start of a study visit unless necessary. Prior to the run-in period, those patients using long-acting β 2 -agonists were permitted regular use of salbutamol for the duration of the run-in period, and for those using inhalers combining inhaled corticosteroids and β 2 -agonists, the steroid component was replaced with equivalent inhaled corticosteroid monotherapy.
Patients on inhaled corticosteroid monotherapy prior to run-in continued on their pre-study regimen. During the treatment phase, all patients received the same inhaled corticosteroid regimen as they received during the run-in period. Patients were not permitted to use any of the following medications during the run-in or treatment periods: tiotropium bromide, ipratropium bromide, combination formulations of β 2 -agonists and inhaled corticosteroids, long-acting β 2 -agonists or short-acting β 2 -agonists (other than salbutamol as above).
Patients were permitted to use theophyllines during the study in recommended and constant dose regimens, providing treatment had been stabilised for at least one month prior to the start of the run-in period. However, such medication was to be withheld on the morning of scheduled clinic visits until after completion of the last spirometry measurement at those visits. visits were kept during the study; patients were asked to return all unused medication at the end of the study.
Assessments

Statistical analyses
Adverse events which began or worsened between starting study treatment and the end of follow-up were summarised. The incidences of tremor, headache and nervousness, which are recognized AEs for the class of drug, were presented with 95% confidence m a n u s c r i p t for each treatment group.
Key variables (serum potassium, blood glucose, pulse rate, systolic and diastolic blood pressure, QTc interval and FEV 1 ) were analysed using a two-way analysis of covariance (ANCOVA) model, with country and treatment as factors and the baseline value of the variable as a covariate. The country effect was treated as fixed and interactions or other effects were not investigated. This type of model provided comparisons between treatment groups at each timepoint while adjusting appropriately for any baseline differences in the variable of focus (note that for all variables analysed in this way there were no significant differences at baseline between active groups and placebo). In each case, the ANCOVA model did not employ repeated measures, but rather applied at each timepoint separately.
Spirometry data other than FEV 1 (i.e. FVC and FEF 25-75% ) were summarised over time, with no additional statistical analyses prespecified. Salbutamol rescue medication was summarised by the average daily number of puffs used between visits, again with no additional statistical analyses prespecified. Safety variables were analysed using results from the safety population (all randomised patients who received at least one dose of study medication), whereas exploratory efficacy analyses were performed using results from the intent-to-treat population (all randomised patients who received at least one dose of study medication and had at least one post-dose FEV 1 measurement).
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Results
Patient characteristics
Patients were recruited from 22 centres in five countries: Belgium, Germany, France, the Netherlands and Slovakia. In total, 253 patients were screened, of whom 163 met the inclusion criteria and were randomised to study treatments; 155 (95%) completed the study.
All randomised patients received at least one dose of the study drug. Of the eight patients who did not complete the study, five withdrew because of protocol violations, 2 withdrew because of AEs (see later for further details) and one patient withdrew consent. Patients were almost exclusively Caucasian (99.4%), aged 40-75 years, with a mean duration of COPD of 7 years (Table 1) .
Baseline patient demographics, lung function and salbutamol use were well balanced, with no statistically significant differences between treatment groups. Although mean FEV 1 reversibility appeared to be relatively high (mean values ranging between 11.2 and 12.7%), patients with a history of asthma had been excluded from the study.
Compliance to treatment was high and similar among treatment groups, with patients in the indacaterol 400 µg and 800 µg and placebo groups receiving treatment for a mean ± SD of 27.0±4.7, 26.9±4.5 and 27.1±2.8 days, respectively.
Safety
The overall AE profile did not suggest any specific toxicity towards a major organ system, and the majority of AEs experienced were mild or moderate in severity. There were no statistically significant differences between treatment groups in the overall AE incidence, Cough was the most frequent AE in the indacaterol treatment groups The difference between treatment groups in the incidence of AEs was largely due to an increased incidence of cough in the indacaterol groups, reported by 10 (14.7%) and 19 (28.4%) patients in the indacaterol 400 and 800 µg groups, respectively, compared with no patients in the placebo group. The majority of cough events were of mild severity, with onset associated with the initial dose of study medication. The incidence of cough declined at subsequent visits, such that at the final dosing visit (Day 28) no patients in any treatment group coughed after study drug administration.
Three patients (4.4%) in the indacaterol 400 µg group and two (7.1%) in the placebo group (compared to no patients in the indacaterol 800 µg group) experienced an exacerbation of their COPD. One of the events in the indacaterol 400 µg group was classified as a serious AE; this occurred 1 week after the patient finished taking study medication. One of the other patients in the indacaterol 400 µg group withdrew from the study as a result of an exacerbation. None of the COPD exacerbations was considered related to study drug treatment.
One other AE led to discontinuation. This also occurred in the indacaterol 400 µg group, in which a patient developed a severe throat irritation which was considered to be related to study medication.
One serious AE occurred in the indacaterol 400 µg group -a COPD exacerbation 1 week after the patient finished taking study medication -however, this was not considered to be related to the study drug. Two AEs led to discontinuation, both in the indacaterol 400 µg group: one patient experienced a COPD exacerbation which was not suspected to be related to the study drug and one patient developed a severe throat irritation which was considered to be related to study medication.
Cardiovascular safety
Pulse rate and blood pressure results are shown in Table 3 . There were no statistically significant differences in pulse rate between indacaterol and placebo groups at The only statistically significant difference between groups in mean systolic blood pressure was seen with indacaterol 800 µg compared with placebo 60 min post-dose on Day 14 (p=0.003; Table 3 ). For mean diastolic blood pressure, the only statistically significant differences were between indacaterol 400 µg and placebo 60 min post-dose on Day 14 (p=0.048), and between indacaterol 400 µg and 800 µg predose on Day 28 (p=0.029).
There was no statistically significant difference between treatments in mean QTc interval at any timepoint using either formula (Table 4) . Using Bazett's formula, only one patient taking indacaterol 800 µg and one patient taking placebo had an increase in QTc interval >60 ms from baseline. Using Fridericia's formula, one patient in the indacaterol 400 µg group and three in the 800 µg group had QTc interval values above the normal range, and one patient in the 800 µg group had an increase in QTc interval >60 ms from baseline.
Laboratory variables and haematology
Post-dose on Day 1, but not on subsequent visits, mean serum potassium was significantly lower in the indacaterol 800 µg group compared to the indacaterol 400 µg (p=0.031) and placebo groups (p=0.029; Table 5 ). One patient in the indacaterol 800 µg group experienced at one timepoint a post-baseline value of 3.4 mmol/l that occurred predose on Day 28.
The only statistically significant difference between groups in mean blood glucose was between indacaterol 800 µg and placebo predose on Day 14 (p=0.009; Table 5 ). Blood glucose values above the normal range (i.e. >7.7 mmol/l) were reported by 5 (7.4%), ten There was no evidence of any drug-or dose-related effects on the majority of the standard haematological tests in any treatment group, and no haematology-related AEs were reported.
Efficacy
There was a marked improvement in FEV 1 in both indacaterol treatment groups at all visits, with a statistically significant improvement vs placebo at all post-baseline timepoints (p<0.01) (Figure 1 ). Since the predose FEV 1 assessment on Days 14 and 28 was approximately 24 hours after inhalation of the previous dose of study medication, this was effectively the 'trough' value, and provided evidence of the duration of action of indacaterol.
Predose adjusted mean±SE FEV 1 improvements compared with placebo on Day 14 were 230±44 ml and 210±44 ml for indacaterol 400 µg and 800 µg, respectively (p<0.0001 vs placebo for both). Corresponding values on Day 28 were 220±49 ml and 210±49 ml (p<0.0001 vs placebo for both).
At 30 minutes post-dose, adjusted mean±SE FEV 1 improvements compared with placebo for indacaterol 400 µg and 800 µg, respectively, were: Day 1, 220±36 ml and 210±36 ml (p<0.0001 vs placebo for both); Day 14, 320±50 ml and 270±50 ml (p<0.0001 vs placebo for both); Day 28, 260±61 ml (p<0.0001 vs placebo) and 200±61 ml (p=0.001 vs placebo).
Indacaterol, but not placebo, demonstrated statistically significant improvements in At all post-baseline timepoints, mean FVC and FEF 25-75% were greater than baseline in both indacaterol groups; values in the placebo group were below baseline at a number of post-baseline timepoints (Table 6 ). In all groups, the number of patients who required rescue salbutamol medication decreased over the course of the study. According to patient estimates, the number of patients not using salbutamol increased from 18% to 60% in the indacaterol 400 µg group, from 16% to 42% in the indacaterol 800 µg group, and from 11%
to 36% in the placebo group.
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Discussion
The present study showed that in patients with COPD, once-daily indacaterol at doses up to 800 µg per day had a good safety profile, was well tolerated and demonstrated 24-hour bronchodilation. As 800 µg represents 2-4 times the therapeutic dose suggested by earlier studies [15] , these results imply that the therapeutic window for indacaterol may be wide. Although the population of this study was originally defined as having moderate COPD, following an update of the GOLD criteria, these patients would now be classified as having moderate-to-severe COPD [1] . Current GOLD Guidelines recommend the use of long-acting bronchodilators for the treatment of patients with COPD classified as moderate onwards, therefore indacaterol, as a novel long-acting β 2 -agonist, has the potential to extend the options available for the treatment of such patients [1] . Salmeterol and formoterol, the two currently available long-acting β 2 -agonists, are recommended to be used twice daily as they have approximately 12-hour durations of action at recommended doses [2] [3] [4] [5] [6] [7] . Previous studies have shown that patients prefer once-daily dosing regimens over twice-daily regimens [16] , which suggests the possibility of improved patient compliance with once-daily indacaterol. In addition, tiotropium, the only once-daily bronchodilator available at present, has been shown to provide superior improvements in lung function and health-related quality of life when compared to four-times-daily dosing with the short-acting anticholinergic ipratropium [8, 9] .
Overall, indacaterol was well tolerated in the current study with no statistically significant differences between treatment groups in the overall incidence of AEs. There was no indication of a relation between the incidence of individual AEs and dose. The only exceptions were the higher number of headaches reported in the indacaterol 800 µg group and the higher incidence of cough in both indacaterol groups compared with placebo. The fact that no patients receiving placebo reported cough may be partly the result of chance, since fewer patients received placebo than indacaterol owing to the 2:2:1 randomisation.
However, most of the episodes of cough were mild in severity and occurred after the first inhalation of study medication, with incidence declining at subsequent visits such that no patients coughed after study drug administration on the final visit. The incidence of cough is therefore not expected to affect the overall tolerability of indacaterol. The characteristics of the cough have been investigated further in other studies: It is of short duration (typically lasting less than two minutes post-dose) and is not associated with bronchospasm. These results will be included in future publications. There were no serious AEs considered to be related to the study drug, and only one patient discontinued because of an AE suspected of being related to indacaterol. In addition, AEs typical of the β 2 -agonist class were generally mild in severity and low in overall incidence, although, as expected, they occurred in the indacaterol treatment groups more frequently than with placebo. The good overall tolerability profile of indacaterol is further supported by the high level of compliance to treatment in this study, and by the very low drop-out rate. In addition, both doses of indacaterol demonstrated a good overall safety profile, with no clinically relevant differences between treatment groups in any of the cardiovascular or biochemical variables assessed.
This study was designed primarily to investigate the safety and tolerability of indacaterol and therefore was not powered to allow definitive conclusions about efficacy.
However, exploratory analyses showed statistically superior increases in FEV 1 for both indacaterol doses compared with placebo, at all post-baseline timepoints, including predose (or trough). This suggests that tolerance to the bronchodilator effects of indacaterol did not develop over 28 days. These results are consistent with those previously observed for indacaterol in a 28-day study in patients with asthma, in which there was no loss of efficacy over the duration of the study [12] . In the current study, clinically relevant improvements in Long-acting β 2 -agonists administered at higher than recommended doses have previously been associated with changes in heart rate, QTc interval and serum potassium and glucose levels, in patients and healthy volunteers [17] [18] [19] [20] [21] [22] [23] . The current study was therefore specifically designed to monitor and assess changes in these variables. There were no clinically relevant differences in serum potassium or blood glucose observed between groups, with isolated statistically significant differences only recorded at two timepoints, both with indacaterol 800 µg. Over the duration of the study, there were no clinically significant effects on pulse rate or blood pressure and no statistically significant differences between indacaterol groups and placebo in mean QTc intervals. Both doses of indacaterol therefore demonstrated a favourable clinical cardiovascular safety profile, supporting data from a previous study in patients with asthma in which indacaterol doses as high as 600 µg were not associated with cardiovascular adverse effects [12] . Overall, the current study does not raise any concerns over the effect of indacaterol on these specific safety variables.
In conclusion, the present study demonstrates that the novel once-daily β 2 -agonist indacaterol is well tolerated at doses up to 800 µg with a good overall safety profile. 
